Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
SARS-CoV-2-specific Humoral and Cell-mediated Immune Responses after Immunization with Inactivated COVID-19 Vaccine in Kidney Transplant Recipients (CVIM 1 Study)
American Journal of Transplantation  (IF8.086),  Pub Date : 2021-10-17, DOI: 10.1111/ajt.16867
Jackrapong Bruminhent, Chavachol Setthaudom, Pongsathon Chaumdee, Sarinya Boongird, Sasisopin Kiertiburanakul, Kumthorn Malathum, Arkom Nongnuch, Angsana Phuphuakrat, Sopon Jirasiritham, Chitimaporn Janphram, Sansanee Thotsiri, Supparat Upama, Montira Assanatham, the Ramathibodi Transplant Infectious Diseases (RTID) Study Group

Immunogenicity following inactivated SARS-CoV-2 vaccination among solid organ transplant recipients has not been assessed. Seventy-five patients (37 kidney transplant [KT] recipients and 38 healthy controls) received two doses, at 4-week intervals, of an inactivated whole-virus SARS-CoV-2 vaccine. SARS-CoV-2-specific humoral (HMI) and cell-mediated immunity (CMI) were measured before, 4 weeks post-first dose, and 2 weeks post-second dose. The median (IQR) age of KT recipients was 50 (42–54) years and 89% were receiving calcineurin inhibitors/mycophenolate/corticosteroid regimens. The median (IQR) time since transplant was 4.5 (2–9.5) years. Among 35 KT patients, the median (IQR) of anti-RBD IgG level measured by CMIA after vaccination was not different from baseline, but was significantly lower than in controls (2.4[1.1–3.7] vs. 1,742.0 [747.7–3,783.0] AU/mL, p<0.01) as well as percentages of neutralizing antibody inhibition measured by surrogate viral neutralization test (0[0-0] vs. 71.2[56.8–92.2]%, p<0.01). However, the median (IQR) of SARS-CoV-2 mixed peptides-specific T-cell responses measured by ELISpot was significantly increased compared with baseline (30[4–120] vs. 12[0–56] T-cells/106 PBMCs, p=0.02) and not different to the controls. Our findings revealed weak HMI but comparable CMI responses in fully vaccinated KT recipients receiving inactivated SARS-CoV-2 vaccination compared to immunocompetent individuals. (Thai Clinical Trials Registry,TCTR20210226002).